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OBJECTIVE: To project the health and economic conse-
quences associated with a prophylactic type-speciﬁc HPV-
16/18 vaccine in the setting of a cervical cancer screening
program. METHODS: A computer-based model of 
the natural history of cervical cancer that incorporates 
the type-speciﬁc HPV distribution within precancerous
lesions and cancer was used to estimate cancer incidence
and mortality, quality-adjusted life years (QALY), lifetime
costs, and incremental cost-effectiveness ratios associated
with different cancer prevention policies consisting of
vaccination, screening, and combined vaccination/screen-
ing strategies. Strategies included (1) no vaccination and
no screening; (2) no vaccination and cytology screening
every 1, 2, 3, 4, and 5 years; (3) vaccination and cytol-
ogy screening every 1, 2, 3, 4, and 5 years. Screening
strategies included conventional and liquid-based cytol-
ogy initiated at ages 18, 21, 25, or 30. We assumed vac-
cination occurred at age 12 and was 90% effective in
reducing the probability of acquiring persistent infection
with HPV 16/18, but evaluated the impact of alternative
assumptions about vaccine efﬁcacy and waning immu-
nity. RESULTS: Vaccination at age 12 followed by trien-
nial cytology screening beginning at age 30 provided
reductions in cervical cancer mortality above those pro-
vided by annual conventional cytology and had an incre-
mental cost-effectiveness ratio of below $50,000 per
QALY compared to the next best strategy of vaccination
and triennial cytology screening beginning at age 35.
These results were stable over a range of vaccine efﬁca-
cies (60% to 100%) but sensitive to the degree to which
vaccination effect persists over time. CONCLUSIONS: A
prophylactic vaccine that prevents persistent HPV 16/18
infection can be expected to signiﬁcantly reduce HPV-
16/18-associated high-grade lesions and cervical cancer
even in a setting of cytology screening. A program of vac-
cination that permits a later age of screening initiation
and a less frequent screening interval is likely to be a cost-
effective use of health care resources.
PIN19
ECONOMIC IMPACT OF ANTIRETROVIRAL
DRUG PRICE REDUCTIONS IN NINE LATIN
AMERICAN COUNTRIES
Becker R, Hill J
Ovation Research Group, Highland Park, IL, USA
OBJECTIVE: A recent agreement to lower the price of
antiretroviral drugs in several Latin American countries
will decrease the cost of treating HIV/AIDS patients to
levels similar to those in Brazil’s established, prototypical
universal access program. This analysis estimates the
likely economic impact of these price reductions in nine
countries (Argentina, Bolivia, Chile, Colombia, Ecuador,
Mexico, Peru, Uruguay, Venezuela) compared to the eco-
nomic impact afforded by Brazil. METHODS: The cost
of two- and three-drug combination antiretroviral was
estimated by applying 2000 Brazilian drug prices (in U.S.
dollars). These costs were multiplied by each country’s
estimated HIV/AIDS population and by the rate of cov-
erage given by Brazil’s universal access program (14.4%
of the HIV/AIDS population). The ratio of these esti-
mated drug costs to gross domestic product (GDP) was
determined to measure each country’s relative ability to
afford treatment. Similar calculations were made to
include cost savings from averted hospitalizations due 
to antiretroviral care. RESULTS: Mexico, Colombia, and
Argentina have the largest HIV/AIDS populations, and
thus, the highest estimated annual drug costs ($91.8
million, $86.1 million, and $79.5 million, respectively).
Bolivia and Uruguay have the lowest costs at $2.8 million
and $3.8 million, respectively. Compared to Brazil’s drug-
cost-to-GDP ratio (0.026%), 6 countries are estimated to
have lower ratios. Chile and Mexico have the lowest
ratios (0.08% and 0.010%, respectively). Only Colombia
(0.032%), Ecuador (0.029%), and Venezuela (0.026%)
have higher ratios equal to or higher than Brazil’s. Savings
from averted hospitalizations reduced overall costs
between 33% and 52% when triple-combination therapy
is included in the program. CONCLUSIONS: For pro-
grams including triple-combination therapy, only Colom-
bia and Ecuador may ﬁnd the new drug program less
affordable than Brazil. Countries with lower drug-cost-
to-GDP ratios should be able to cover a higher percent-
age of patients than Brazil.
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OBJECTIVES: The purpose of this study was to assess
the cost-effectiveness of drotrecogin alfa (activated)
(DAA) as an adjunct to standard therapy compared to
standard therapy alone for Swedish patients with severe
sepsis by using 1) country speciﬁc cost and resource data
compared to 2) exchange rate transferring of a UK model
application based on the results from the clinical trial and
UK treatment patterns. METHODS: In the PROWESS
trial DAA has been found to decrease the all cause 28-
day mortality in adult patients with severe sepsis. A C/E
model was developed for estimating costs and outcomes
and could be applied taking account of local treatment
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patterns, costs, life expectancy, and discount rates.
Patients with both an infection and at least one acute
organ dysfunction diagnosis (ICD-10) recorded were
selected from Huddinge university hospital in Sweden (n
= 55). Direct costs for drugs, intensive care, and general
wards up to 28 days, and to ﬁnal discharge were deter-
mined according to the hospital resource and cost assign-
ment system (2002 prices). The cost of DAA was based
on the average use in the trial and the Swedish price 2002.
RESULTS: The cost-effectiveness ratio of an adjunct
drotrecogin alfa (activated) compared with standard
therapy alone in the base case including patients with
failure in at least two organs was €19,500 per QALY
based on Swedish data. The corresponding ﬁgure was
€13,700 when results were transferred by the exchange
rate. Higher ICU costs in Sweden compared to UK
account for 45% of the difference whereas higher life
expectancy among the UK patients account for 55%.
CONCLUSIONS: Drotrecogin alfa (activated) is cost-
effective when compared to other accepted Health care
interventions in Sweden. Local data application is im-
portant but does in this case not change the overall 
conclusion.
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OBJECTIVES: The dynamic infectious disease model
EVITA (Economic Varicella VaccInation Tool for Analy-
sis) has shown cost-effectiveness of universal varicella
vaccination of children in Germany (Banz et al. 2003).
However, affordability proves to be an additional hurdle.
The aim of this analysis is to examine budget impacts of
universal varicella vaccination from a payers’ perspective.
METHODS: EVITA was used to analyse budget impacts
over 30 years (price level of 2002). Future costs were not
discounted to show the full budget impact in future years.
Targeted age-group for vaccination are children aged 1
year. Because in Germany no liability of vaccination for
Kindergarten or school entry exists unlike in several US-
states, we conservatively assumed coverage to increase
linear from 7% to a maximum of 85% within 9 years
and remain constant afterwards. These projected ﬁgures
correspond to the slowest uptake in US-states in the ﬁrst
6 years of universal varicella vaccination. RESULTS:
Without vaccination, annual varicella costs amount to
€72.6 million (23% outpatient, 25% inpatient, 52%
work loss of parents staying at home to care for their sick
child). Vaccination costs rise (proportional to coverage)
from €3.9 to a maximum of €37.4 million and account
at maximum for 0.03% of total payers’ health care
budget. Compared to no vaccination, varicella-related
costs, i.e. varicella and vaccination cost, increase by 12%
in the ﬁrst 3 years. Then, savings through reduced mor-
bidity occur which offset vaccination costs after 5 years.
Over 30 years, average annual costs are reduced by 32%
to €49.7 million. CONCLUSIONS: Varicella vaccination
has a small impact on health care costs and does not inﬂu-
ence insurance premiums. For a short time, investment in
varicella vaccination causes additional costs, which are
low compared to annual varicella costs. Reduced mor-
bidity leads rapidly to savings. In the longer term signif-
icant net-savings occur.
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A safe, effective vaccine for chickenpox (varicella zoster)
is available. However, some countries do not consider
varicella vaccination a priority when compared with
other childhood infectious diseases. It is important to Por-
tuguese health policy to determine the economic value of
vaccinating healthy children against chickenpox. OBJEC-
TIVE: To estimate the cost-effectiveness of universal vari-
cella vaccination compared with vaccination on demand.
Design: Cost-utility analysis. Data sources: Costs were
estimated from government sources (Administração
Regional de Saúde de Lisboa e Vale do Tejo); vaccine efﬁ-
cacy data and utility values were derived from reports of
clinical studies published in the peer-reviewed literature.
Target Population: Portuguese children age 15 month.
Time Horizon: Ten years. Perspective: Societal. Interven-
tions: Universal vaccination as part of the National Vac-
cination Programme or the current situation in which
vaccination is given on demand to children whose parents
request it or can afford to pay for it. Outcomes measures:
Costs, quality-adjusted life years (QALYs), cases of chick-
enpox prevented, and average cost-effectiveness ratios.
Results of Base-Case Analysis: The average cost-
effectiveness ratio proved to be dominant for the univer-
sal program compared with the actual situation. The cost
per QALY is €16 or for each case prevented of €23. On
demand vaccination is dominated by a the universal vac-
cination option, costing more and resulting in fewer
QALYs and cases of chickenpox prevented. No substan-
tive alteration of the base-case was noticed in a sensitivity
analysis. CONCLUSIONS: A universal varicella vaccina-
tion program would be expected to improve quality of
life and reduce the health care expenditures when used in
young children.
